ERBB2 and non-small cell lung carcinoma: In a separate phase II clinical study, T‐DM1 was administered to forty‐nine previously treated patients with advanced HER2‐overexpressing NSCLC (IHC 2+, 29; IHC 3+, 20) to evaluate its efficacy.117